webinar series
Valsartan Sacubitril: Has our PARADIGM shifted?
A to Z of CV Pharmacotherapy: Webinar Series
This webinar is the fourth in a series of webinars from the ISCP, produced by Radcliffe Cardiology, focusing on the A to Z of CV Pharmacotherapy.
Webinars in this series include:
For more details on upcoming webinars please visit our upcoming events section.
This webinar is an independent activity run by the International Society of Cardiovascular Pharmacotherapy (ISCP). The ISCP has been provided support to develop this webinar by Novartis Singapore. The supporter has had no influence on the content of the programme or provided any funding to Radcliffe Cardiology.
Overview
Patients with heart failure with preserved ejection fraction (HFpEF) suffer from poor survival, high hospitalisations rate and long-term mortality. HFpEF patients are often overlooked as compared to the more well-known HFrEF where the famous “fantastic four” are now well-known as disease-modifying therapies. The plethora of evidence-based studies have time and again proven their value in the modification of the untoward outcomes in the latter.
A recent ARNI trial has shown potential benefits of valsartan sacubitril on patients with HFpEF. Does that change the paradigm of how HFpEF should now be treated? Let us explore how we could apply the trial findings into our real-world clinical practice.
Learning Objectives
To evaluate and understand which patients should and should not be prescribed valsartan sacubitril and which patients groups might benefit most;
To determine how valsartan sacubitril should be administered and what dosage adjustments and drug interactions need to be noted;
To analyse special and regional issues that impact the use of this drug;
To apply evidence-based recommendations to two real-world cases.
Target Audience
Cardiovascular team members - doctors, nurses, pharmacists
Family physicians
Internists
Cardiovascular pharmacotherapy researchers
Faculty
Led by moderators Janice Wong (Malaysia) and Doreen Tan (Singapore), it includes a speaker presentation from Giuseppe Rosano (UK) and a discussion from panelists Richard Henry Tiongco (Philippines) and Rungroj Krittayphong (Thailand) that will examine the potential use of this agent in HFpEF population, through consideration of real-world examples, live discussions, and audience Q&A.
Performed by:
Presenter
restricted content
ISCP Members Only
Access to the e-Learning and Experts sections is available to ISCP Members only. Already a Member? Log in Not yet a Member? Visit our Registration page for details of how to join the ISCP and learn more about the benefits of being a part.